P3 Health PartnersPIII
PIII
About: P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
Employees: 360
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
1.7% less ownership
Funds ownership: 12.42% [Q4 2024] → 10.72% (-1.7%) [Q1 2025]
13% less funds holding
Funds holding: 39 [Q4 2024] → 34 (-5) [Q1 2025]
37% less capital invested
Capital invested by funds: $4.57M [Q4 2024] → $2.9M (-$1.67M) [Q1 2025]
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
199%
upside
Avg. target
$20
199%
upside
High target
$20
199%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Brooks O'Neil | 199%upside $20 | Buy Maintained | 21 Apr 2025 |
Financial journalist opinion
Based on 6 articles about PIII published over the past 30 days
Negative
Zacks Investment Research
3 days ago
Bears are Losing Control Over P3 Health Partners (PIII), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for P3 Health Partners (PIII), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
1 week ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Neutral
GlobeNewsWire
1 week ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a distinguished law firm with over 125 years of history, announces it is investigating claims on behalf of investors of P3 Health Partners, Inc. (NASDAQ: PIII) (“P3” or the “Company”). (NASDAQ: PIII)
Neutral
GlobeNewsWire
2 weeks ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Positive
Zacks Investment Research
2 weeks ago
Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)
The heavy selling pressure might have exhausted for P3 Health Partners (PIII) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
GlobeNewsWire
3 weeks ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Neutral
Seeking Alpha
1 month ago
P3 Health Partners Inc. (PIII) Q1 2025 Earnings Call Transcript
P3 Health Partners Inc. (NASDAQ:PIII ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Ryan Halstead - Managing Director, Gilmartin Group LLC, IR Aric Coffman - CEO Leif Pedersen - CFO Amir Bacchus - Chief Medical Officer Conference Call Participants Josh Raskin - Nephron Research Ryan Langston - TD Cowen Operator Good day, and welcome to the P3 Health Partners First Quarter 2025 Earnings Conference Call. All participants will be in listen-only-mode.
Negative
Zacks Investment Research
1 month ago
P3 Health Partners Inc. (PIII) Reports Q1 Loss, Tops Revenue Estimates
P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.28 per share versus the Zacks Consensus Estimate of a loss of $5. This compares to loss of $8 per share a year ago.
Neutral
Business Wire
1 month ago
P3 Health Partners Announces First Quarter 2025 Results
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended March 31, 2025, and affirmed its 2025 guidance. “Our physician-led care enablement model continues to differentiate P3, delivering meaningful improvements in quality measures and cost management through deeper provider partnerships,” said Aric Coffman, CEO of.
Neutral
Business Wire
1 month ago
P3 Health Partners Schedules First Quarter 2025 Earnings Release and Conference Call
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for first quarter 2025 and file its Quarterly Report on Form 10-Q on Thursday, May 15, 2025. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health First.
Charts implemented using Lightweight Charts™